Roivant Sciences (NASDAQ:ROIV) Major Shareholder Vivek Ramaswamy Sells 353,745 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) major shareholder Vivek Ramaswamy sold 353,745 shares of Roivant Sciences stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $22.05, for a total value of $7,800,077.25. Following the completion of the transaction, the insider owned 34,132,463 shares of the company’s stock, valued at approximately $752,620,809.15. The trade was a 1.03% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Vivek Ramaswamy also recently made the following trade(s):

• On Thursday, December 11th, Vivek Ramaswamy sold 774,142 shares of Roivant Sciences stock. The shares were sold at an average price of $21.64, for a total value of $16,752,432.88.
• On Friday, December 12th, Vivek Ramaswamy sold 1,975,858 shares of Roivant Sciences stock. The stock was sold at an average price of $21.96, for a total transaction of $43,389,841.68.
• On Monday, November 17th, Vivek Ramaswamy sold 539,650 shares of Roivant Sciences stock. The shares were sold at an average price of $20.51, for a total transaction of $11,068,221.50.
• On Friday, November 14th, Vivek Ramaswamy sold 1,027,670 shares of Roivant Sciences stock. The stock was sold at an average price of $20.33, for a total transaction of $20,892,531.10.
• On Thursday, November 13th, Vivek Ramaswamy sold 287,283 shares of Roivant Sciences stock. The shares were sold at an average price of $20.81, for a total transaction of $5,978,359.23.

Roivant Sciences Stock Down 0.9%

Shares of NASDAQ:ROIV opened at $21.90 on Tuesday. The company has a market cap of $15.23 billion, a PE ratio of -39.11 and a beta of 1.22. Roivant Sciences Ltd. has a fifty-two week low of $8.73 and a fifty-two week high of $22.56. The firm has a 50-day simple moving average of $19.49 and a 200 day simple moving average of $14.81.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Citigroup upped their target price on Roivant Sciences from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. Jefferies Financial Group upped their price objective on Roivant Sciences from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday, September 18th. JPMorgan Chase & Co. increased their target price on Roivant Sciences from $16.00 to $20.00 and gave the stock an “overweight” rating in a research report on Thursday, September 18th. The Goldman Sachs Group boosted their price target on shares of Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a report on Monday. Finally, HC Wainwright increased their price objective on shares of Roivant Sciences from $23.00 to $26.00 and gave the stock a “buy” rating in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.81.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Jones Financial Companies Lllp grew its position in Roivant Sciences by 226.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock valued at $25,000 after buying an additional 1,148 shares in the last quarter. Allworth Financial LP lifted its stake in shares of Roivant Sciences by 48.1% in the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after acquiring an additional 583 shares during the period. Bessemer Group Inc. boosted its holdings in shares of Roivant Sciences by 41.5% in the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after acquiring an additional 543 shares in the last quarter. CWM LLC increased its stake in shares of Roivant Sciences by 44.6% during the second quarter. CWM LLC now owns 2,984 shares of the company’s stock valued at $34,000 after acquiring an additional 920 shares during the period. Finally, Aster Capital Management DIFC Ltd raised its holdings in Roivant Sciences by 75.8% during the third quarter. Aster Capital Management DIFC Ltd now owns 4,405 shares of the company’s stock worth $67,000 after purchasing an additional 1,900 shares in the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.